KNSA Kiniksa Pharmaceuticals PE ratio, current and historical analysis
- Stocks
- Healthcare
- NASDAQ: KNSA
- PE Ratio
The price-to-earnings ratio for Kiniksa Pharmaceuticals stock stands at 79.88 as of Nov 5, 2025. This is calculated based on the current EPS of $0.49 and the stock price of $39.14 per share.
KNSA PE ratio history
Over the last four years, the average PE ratio of Kiniksa Pharmaceuticals has been 101.56. The current 79.88 PE ratio is 21% below the historical average. In the past four years, KNSA's PE ratio was at its highest in the Jun 2025 quarter at 461.17, with a price of $27.67 and an EPS of $0.06. The Mar 2023 quarter recorded the bottom point at 3.82, with a price of $10.76 and an EPS of $2.82.
Kiniksa Pharmaceuticals PE ratio by year
Maximum annual increase: 1,446.74% in 2023
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| 2024 | N/A | N/A | $19.78 | -$0.6 |
| 2023 | 87.7 | 1,446.74% | $17.54 | $0.2 |
| 2022 | 5.67 | N/A | $14.98 | $2.64 |
| 2021 | N/A | N/A | $11.77 | -$2.3 |
| 2020 | N/A | N/A | $17.67 | -$2.61 |
| 2019 | N/A | N/A | $11.06 | -$2.99 |
| 2018 | N/A | N/A | $28.09 | -$3.49 |
| 2017 | N/A | N/A | N/A | -$35.85 |
| 2016 | N/A | N/A | N/A | -$91.61 |
Kiniksa Pharmaceuticals PE ratio by quarter (TTM)
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| Sep 2025 | 79.24 | -82.82% | $38.83 | $0.49 |
| Jun 2025 | 461.17 | N/A | $27.67 | $0.06 |
| Mar 2025 | N/A | N/A | $22.21 | -$0.24 |
| Dec 2024 | N/A | N/A | $19.78 | -$0.6 |
| Sep 2024 | N/A | N/A | $24.99 | -$0.13 |
| Jun 2024 | N/A | N/A | $18.67 | -$0.15 |
| Mar 2024 | 164.42 | 87.48% | $19.73 | $0.12 |
| Dec 2023 | 87.7 | N/A | $17.54 | $0.2 |
| Sep 2023 | N/A | N/A | $17.37 | -$0.11 |
| Jun 2023 | 4.24 | 10.99% | $14.08 | $3.32 |
| Mar 2023 | 3.82 | -32.63% | $10.76 | $2.82 |
| Dec 2022 | 5.67 | -8.99% | $14.98 | $2.64 |
| Sep 2022 | 6.23 | N/A | $12.84 | $2.06 |
| Jun 2022 | N/A | N/A | $9.69 | -$1.61 |
| Mar 2022 | N/A | N/A | $9.94 | -$1.93 |
KNSA Price vs fair value
KNSA average PE ratio chart
Currently, KNSA's PE ratio is lower than the 3 and 5-year averages.
PE comparison
With a P/E of 79.88, KNSA stands above the Healthcare sector and the industry average. Compared to its Healthcare sector average of 25.01, Kiniksa Pharmaceuticals's P/E is 219% higher.
KNSA PE vs peers
| Stock name | PE ratio | Market cap |
|---|---|---|
| KNSA Kiniksa Pharmaceuticals Ltd | 79.88 | $2.97B |
| OLMA Olema Pharmaceuticals Inc | N/A | $545.64M |
| OMER Omeros Corp | N/A | $475.71M |
| VIVS VivoSim Labs Inc. | N/A | $5.93M |
| ORIC Oric Pharmaceuticals Inc | N/A | $1.2B |
| ORMP Oramed Pharmaceuticals Inc | N/A | $91.85M |
Frequently asked questions
What is Kiniksa Pharmaceuticals's PE ratio?
The price to earnings ratio for KNSA stock as of Nov 5, 2025, stands at 79.88.
What is the 3-year average PE ratio for Kiniksa Pharmaceuticals (KNSA)?
Over the last 3 years, the average price to earnings ratio for KNSA stock is 115.18.
What is the 5-year average PE ratio for Kiniksa Pharmaceuticals (KNSA)?
Over the last 5 years, the average price to earnings ratio for KNSA stock is 101.56.
What is the highest PE ratio for KNSA?
Over the last four years, the quarterly PE ratio reached a historic high of 461.17 in the Jun 2025 quarter.
How does the current PE ratio for KNSA compare to its historical average?
The current price to earnings ratio of KNSA is 21% lower than the 4-year historical average.
Why is Kiniksa Pharmaceuticals's PE ratio so high?
KNSA's PE ratio of 79.88 is considered high because the company's stock price is trading at a higher multiple of earnings.
How is KNSA's PE ratio calculated (Kiniksa Pharmaceuticals PE ratio formula)?
To determine the PE ratio, divide the most recent stock price by the TTM earnings per share (EPS). As of today (Nov 5, 2025), Kiniksa Pharmaceuticals's stock price is $39.14. The earnings per share for the trailing twelve months (TTM) ending Sep 2025 is $0.49. Therefore, Kiniksa Pharmaceuticals's P/E ratio for today is 79.88. PE RATIO(79.88) = STOCK PRICE($39.14) / TTM EPS($0.49)
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified.